Adagene Inc. (ADAG) Tuesday said it has received feedback from the United States Food and Drug Administration (FDA) on its clinical development plan to evaluate muzastotug in combination with Merck's cancer immunotherapy drug Keytruda in patients with microsatellite stable colorectal cancer (MSS CRC).
The company plans to begin enrolling patients in Phase 2 study of muzastotug in the second half of this year.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.